Atea Pharmaceuticals
AVIR
127 hedge funds and large institutions have $406M invested in Atea Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 42 reducing their positions, and 18 closing their positions.
1,394% more call options, than puts
Call options by funds: $14M | Put options by funds: $935K
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
3.05% more ownership
Funds ownership: 66.02% → 69.07% (+3%)
3% more capital invested
Capital invested by funds: $396M → $406M (+$10.1M)
0% more funds holding
Funds holding: 127 → 127 (0)
10% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$12.2M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$11M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.5M |
| 4 |
BlackRock
New York
|
+$5.34M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$8.84M |
| 2 |
Voloridge Investment Management
Jupiter,
Florida
|
-$3.75M |
| 3 |
Renaissance Technologies
New York
|
-$3.43M |
| 4 |
Two Sigma Investments
New York
|
-$3.36M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.89M |
AVIR Hedge Fund Activity: Q2 2022 in Review
127 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q2 2022, worth a combined $406M — up 2.5% from $396M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new AVIR positions and 18 closed out — a net gain of 4 holders — while 38 added to existing stakes and 42 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $12.2M. The largest seller was Citadel Advisors, cutting an estimated $8.84M.
- 127 institutional investors held Atea Pharmaceuticals (AVIR) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $406M of Atea Pharmaceuticals stock for Q2 2022, up 2.5% quarter-over-quarter.
- 22 funds opened new Atea Pharmaceuticals positions in Q2 2022 and 18 closed out, a net change of +4 holders.
- The largest Atea Pharmaceuticals buyer in Q2 2022 was Balyasny Asset Management, an estimated $12.2M added.
- The largest Atea Pharmaceuticals seller in Q2 2022 was Citadel Advisors, an estimated $8.84M sold.
Based on aggregated 13F filings for Q2 2022.